{
  "templates": {
    "base": {
      "tool_data": {
        "description": "Provide predictions for the outcome of the clinical trial in question, and provide the reasoning behind the decision. If the success of the trial is unlikely, or you are uncertain in your decision, choose to classify it as a failure.",
        "parameters": {
          "type": "object",
          "properties": {
            "prediction": { "type": "string", "enum": ["success", "failure"] }
          },
          "required": ["prediction"]
        }
      },
      "summary_prompt": "You are an expert in clinical pharmacology, tasked with examining which clinical trials are worthy of investment, and which ones have a higher likelihood of failure."
    },
    "cot": {
      "tool_data": {
        "description": "Provide predictions for the outcome of the clinical trial in question, and provide the reasoning behind the decision.Take into account the nature of a clinical trial, the disease risk, the drug, and past knowledge about the type of trial. If the success of the trial is unlikely, or you are uncertain in your decision, choose to classify it as a failure. Provide adequate reasoning and bear the realities of clinical trials in mind at each step of reasoning.",
        "parameters": {
          "type": "object",
          "properties": {
            "reasoning": {
              "type": "string",
              "description": "The step-by-step reasoning behind the prediction of trial success or failure, including the nature of the clinical trial, the disease risk, and the eligibility criteria."
            },
            "prediction": { "type": "string", "enum": ["success", "failure"] }
          },
          "required": ["reasoning", "prediction"]
        }
      },
      "summary_prompt": "You are an expert in clinical pharmacology, tasked with examining which clinical trials are worthy of investment, and which ones have a higher likelihood of failure."
    },
    "cot+clinical_knowledge": {
      "tool_data": {
        "description": "Provide predictions for the outcome of the clinical trial in question, and provide the reasoning behind the decision.Take into account the nature of a clinical trial, the disease risk, the drug, and past knowledge about the type of trial. If the success of the trial is unlikely, or you are uncertain in your decision, choose to classify it as a failure. Provide adequate reasoning and bear the realities of clinical trials in mind at each step of reasoning.",
        "parameters": {
          "type": "object",
          "properties": {
            "reasoning": {
              "type": "string",
              "description": "The step-by-step reasoning behind the prediction of trial success or failure, including the nature of the clinical trial, the disease risk, and the eligibility criteria."
            },
            "prediction": { "type": "string", "enum": ["success", "failure"] }
          },
          "required": ["reasoning", "prediction"]
        }
      },
      "summary_prompt": "You are an expert in clinical pharmacology, tasked with examining which clinical trials are worthy of investment, and which ones have a higher likelihood of failure. In spite of time-consuming processes and high costs, the overall success rate of clinical trials is only 7.9%, which is a high risk for biopharmaceutical companies.\nThe four most important success factors according to research are the following: quality of clinical trials, speed of clinical trials, relationship type, and communication.\nPatient registration is a key factor in determining the success of clinical trials, and an analysis of clinical trials showed that 19% of clinical trials were terminated due to insufficient numbers of participants. Among the clinical trials that were terminated, many cases were found that were terminated due to failure in patient registration.\nThe speed of clinical trials is important when companies select clinical trial partners for rapid clinical trial progress.\nIn addition, it has been found that rapid patient recruitment for clinical trials affects the speed of clinical trial completion.\nIn terms of communication, Getz discovered that research sites with sufficient infrastructure for clinical trials are 41% better than sites dedicated to clinical trials in terms of patient enrollment.\nThe quality of clinical trials is an important indicator for moving clinical trials to the next stage.\nRegarding the quality of clinical trials, it was found that the adequacy of clinical trial planning and operation was the main characteristic.\nQuality in clinical trials also means the quality of GCP compliance.\nThe duration of clinical trials is a key factor in determining the financial risks and rewards of drug development projects.\nThe duration of clinical trials is 2.7 years, 3.2 years, and 3.8 years, respectively, for Phase 1, 2, and 3 trials, and the success rate from clinical trial success to new drug approval is less than 7.9%.\nRegarding the type of relationship between the sponsor and the collaborator,the success rate of clinical trials with partnerships was high.\nThe success rate of a new drug development project based on the number of non-industrial partners, not the pharmaceutical industry, and confirmed that the success rate of clinical trials increased by 11.3 percentage points when non-industrial partners participated. In many existing studies related to communication, it was found that close communication between the sponsor and the collaborator affects the success of clinical trials."
    },
    "subtasks+clinical_knowledge": {
      "tool_data": {
        "description": "Provide predictions for the outcome of the clinical trial in question, and provide the reasoning behind the decision.Take into account the nature of a clinical trial, the disease risk, the drug, and past knowledge about the type of trial. If the success of the trial is unlikely, or you are uncertain in your decision, choose to classify it as a failure. Provide adequate reasoning and bear the realities of clinical trials in mind at each step of reasoning.",
        "parameters": {
          "type": "object",
          "properties": {
            "reasoning": {
              "type": "string",
              "description": "The step-by-step reasoning behind the prediction of trial success or failure, including the nature of the clinical trial, the disease risk, and the eligibility criteria."
            },
            "prediction": { "type": "string", "enum": ["success", "failure"] }
          },
          "required": ["reasoning", "prediction"]
        }
      },
      "base_messages": [
        {
          "role": "user",
          "content": "You are an expert in clinical pharmacology, tasked with examining which clinical trials are worthy of investment, and which ones have a higher likelihood of failure. In spite of time-consuming processes and high costs, the overall success rate of clinical trials is only 7.9%, which is a high risk for biopharmaceutical companies.\nThe four most important success factors according to research are the following: quality of clinical trials, speed of clinical trials, relationship type, and communication."
        },
        {
          "role": "assistant",
          "content": "Evaluating clinical trials for investment involves a nuanced understanding of the factors that influence their success. Given the low overall success rate of 7.9%, it's crucial to scrutinize these factors closely to mitigate financial risks and maximize the potential for positive outcomes. Here's a breakdown of the key success factors, and how they impact the likelihood of clinical trial success: ### Quality of Clinical Trials - **Definition**: Encompasses the adherence to Good Clinical Practice (GCP) guidelines, the adequacy of planning and operation, and the overall conduct of the trial. - **Impact**: High-quality trials are more likely to produce reliable, replicable results, advancing to subsequent trial phases and ultimately gaining regulatory approval. Investments should prioritize trials demonstrating rigorous design, clear objectives, and thorough planning. ### Speed of Clinical Trials - **Definition**: Refers to the pace at which clinical trials progress, from patient recruitment to data analysis. - **Impact**: Speed is critical for maintaining cost-efficiency and achieving timely results. Fast-recruiting and efficiently managed trials can reduce overhead costs and accelerate the time to market for promising therapies. However, speed should not compromise the quality or integrity of the trial. ### Relationship Type - **Definition**: The nature of the partnership between the trial sponsor (often a biopharmaceutical company) and collaborators (research institutions, non-industrial partners, etc.). - **Impact**: Collaborative relationships characterized by mutual trust, aligned goals, and effective communication are more likely to succeed. Trials involving non-industrial partners have shown an increased success rate, suggesting that diverse expertise and resources can enhance trial outcomes. ### Communication - **Definition**: The effectiveness of information exchange among all stakeholders involved in a clinical trial, including sponsors, collaborators, participants, and regulatory bodies. - **Impact**: Effective communication ensures that trials are conducted efficiently, with timely recruitment and retention of participants. It also facilitates quick resolution of issues and enhances adherence to protocols and regulatory requirements. ### Patient Registration - **Critical Issue**: Insufficient participant numbers leading to trial termination. - **Strategy**: Emphasizing trials that demonstrate effective recruitment strategies and have a clear plan for participant engagement is essential. Trials with infrastructure supporting efficient patient enrollment and retention are preferable. ### Duration of Clinical Trials - **Observation**: The average duration varies by phase, impacting the financial and temporal investment required. - **Consideration**: Longer trials necessitate more substantial investment and carry greater risk. However, a well-planned, longer trial that addresses an unmet medical need may justify the investment due to the potential for significant clinical and financial rewards. ### Investment Recommendations 1. **Prioritize Quality and Planning**: Select trials that demonstrate rigorous planning, clear objectives, and adherence to GCP. 2. **Evaluate Speed and Efficiency**: Look for trials with proven strategies for rapid recruitment and streamlined operations. 3. **Assess Relationships and Communication**: Choose collaborations characterized by strong, effective communication and shared goals. 4. **Consider Participant Recruitment**: Focus on trials with solid recruitment plans and infrastructure to support participant engagement. 5. **Weigh Duration Against Potential Impact**: Be mindful of the trial's phase duration but consider the broader potential for significant medical and financial returns. Investing in clinical trials requires a balanced approach that considers these factors in concert. By focusing on trials that demonstrate excellence across these domains, investors can better navigate the inherent risks and identify opportunities with the highest potential for success."
        }
      ],
      "questions": [
        {
          "role": "user",
          "content": "Let' examine the disease and the used compounds. How treatable is the condition, and what risk does the treatment entail? How could this affect the trial's outcome?"
        },
        {
          "role": "user",
          "content": "Patient registration is a key factor in determining the success of clinical trials, and an analysis of clinical trials showed that 19% of clinical trials were terminated due to insufficient numbers of participants. Among the clinical trials that were terminated, many cases were found that were terminated due to failure in patient registration. Based on the eligibility criteria and the nature of the disease, how hard will it be to find a sufficient amount of patients?"
        }
      ],
      "summary_prompt": "Let's wrap this up and go over the factors we have discussed previously. Then, assess the feasibility of the clinical trial and predict whether the trial is more likely to fail or to succeed. Provide adequate reasoning for each step of the process."
    }
  },
  "examples": {
    "one_shot": []
  }
}
